Abstract
Ipragliflozin is a sodium-glucose co-transporter 2 inhibitor that can improve glycemic control and reduce body weight and blood pressure in patients with type 2 diabetes mellitus (T2DM). We evaluated the efficacy and safety of ipragliflozin in the real-world clinical setting, with a focus on the changes of body composition up to 3 months of treatment. This was a prospective multicenter interventional trial. We investigated changes of the blood pressure, body composition, blood glucose, hemoglobin A1c (HbA1c), ketone bodies, lipids, and insulin after treatment with ipragliflozin (50 - 100 mg/day) for 12 weeks in Japanese patients with T2DM who showed poor glycemic control despite receiving diet and exercise therapy with or without oral antidiabetic drugs for more than 12 weeks. Two hundred and fifty-seven subjects were included in the efficacy analysis up to 12 weeks of treatment and 301 subjects were included in the safety analysis. From baseline to 12 weeks, HbA1c showed a change of -0.68% (95% confidence interval (CI): -0.83, -0.53) and fasting blood glucose showed a change of -23.9 mg/dL (95% CI: -30.5, -17.2), with both parameters displaying a significant reduction (P < 0.001). The difference of body weight from baseline wa...Continue Reading
Citations
Jul 20, 2016·Oxidative Medicine and Cellular Longevity·José Pedraza-ChaverriAlexandra Scholze
Jul 28, 2016·Expert Opinion on Pharmacotherapy·Hiroshi MaegawaIchiro Nakamura
Sep 14, 2016·Cardiovascular Diabetology·Atsushi TanakaUNKNOWN PROTECT Study Investigators
Sep 7, 2016·Expert Opinion on Pharmacotherapy·Hiroyuki ItoMariko Abe
May 2, 2017·Biological & Pharmaceutical Bulletin·Toshiyuki TakasuShoji Takakura
Feb 9, 2017·Diabetes, Obesity & Metabolism·Takashi KadowakiMaki Gouda
Dec 27, 2016·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Yoshio SumidaUNKNOWN Japan Study Group of NAFLD (JSG-NAFLD)
Jun 8, 2018·Circulation Journal : Official Journal of the Japanese Circulation Society·Takahiro Okumura, Toyoaki Murohara
Jul 27, 2018·Endocrine Journal·Shinya FurukawaYoichi Hiasa
Mar 16, 2016·PloS One·Chikara KomiyaYoshihiro Ogawa
Feb 6, 2019·Journal of Diabetes Investigation·Kazuyuki TobeSatoshi Uno
Mar 10, 2020·Journal of Diabetes Investigation·Ikuro MatsubaYasushi Tanaka
Aug 29, 2019·Cardiovascular Diabetology·Sho KinguchiKouichi Tamura
Jun 24, 2020·BMJ Open·Shun YamashitaShu-Ichi Yamashita
Aug 28, 2020·Advances in Therapy·Dan LiuHongyan Wu
Jun 24, 2017·Journal of Diabetes Investigation·Takeshi OsonoiYusuke Osonoi
Nov 3, 2016·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Toshiyuki TakasuKaori Hamada
Mar 7, 2018·Journal of Diabetes Research·Shinji KameiHideaki Kaneto
Apr 7, 2019·Cardiovascular Diabetology·Anja SchorkFerruh Artunc
Jun 19, 2018·Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association·Ahmed ElgebalyNoha Nasreldin
Jan 15, 2021·Scientific Reports·Sho KinguchiKouichi Tamura
Jan 5, 2021·Endocrine Journal·Ryotaro BouchiYoshihiro Ogawa
Aug 3, 2021·Diabetes, Obesity & Metabolism·Ikuro MatsubaAkira Kanamori